公开(公告)号：US20210283169A1

公开(公告)日：2021-09-16

申请号：US17215195

申请日：2021-03-29

Applicant: HiberCell, Inc.

Inventor： Nandita Bose ,  Keith Gorden ,  Anissa SH. Chan ,  Steven Leonardo ,  Jeremy Graff ,  Xiaohong Qiu ,  Takashi Kangas ,  Kathryn A. Fraser ,  Adria Bykowski Jonas ,  Nadine Ottoson ,  Ross Fulton

IPC: A61K31/716 ,  C12N5/0783 ,  A61K39/395 ,  C07K16/28 ,  C12N5/0784 ,  C12N5/0786 ,  C07K16/30

Abstract: This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

公开(公告)号：US20240350528A1

公开(公告)日：2024-10-24

申请号：US18493604

申请日：2023-10-24

Applicant: HiberCell, Inc.

Inventor： Nandita Bose ,  Keith Gorden ,  Anissa SH. Chan ,  Steven Leonardo ,  Jeremy Graff ,  Xiaohong Qiu ,  Takashi Kangas ,  Kathryn A. Fraser ,  Adria Bykowski Jonas ,  Nadine Ottoson ,  Ross Fulton

IPC: A61K31/716 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44 ,  A61K39/00

CPC classification number: A61K31/716 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/22 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/44 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/73

Abstract: The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.